Abstract
A novel PCD/CUR self-assembly approach for improved curcumin delivery to prostate cancer cells is described. The formation of PCD/CUR was confirmed using FTIR, DSC, TGA, and SEM/TEM, and their stability and solubility under physiological conditions was demonstrated. A mechanism for self-assembly is proposed. Intracellular uptake of the self-assemblies was studied by flow cytometry and immunofluorescence microscopy. The therapeutic efficacy was determined by cell proliferation and colony formation assays using C4-2, DU145 and PC3 prostate cancer cells. The results suggest that the PCD/CUR formulation could be a useful system for improving curcumin delivery and its therapeutic efficacy in prostate cancer.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Antineoplastic Agents* / administration & dosage
-
Antineoplastic Agents* / chemistry
-
Antineoplastic Agents* / therapeutic use
-
Cell Line, Tumor
-
Curcumin* / administration & dosage
-
Curcumin* / chemistry
-
Curcumin* / therapeutic use
-
Drug Delivery Systems
-
Humans
-
Male
-
Models, Molecular
-
Propylene Glycols / administration & dosage
-
Propylene Glycols / chemistry
-
Propylene Glycols / therapeutic use
-
Prostatic Neoplasms / drug therapy*
-
beta-Cyclodextrins / administration & dosage
-
beta-Cyclodextrins / chemistry
-
beta-Cyclodextrins / therapeutic use
Substances
-
Antineoplastic Agents
-
Propylene Glycols
-
beta-Cyclodextrins
-
poly(beta-cyclodextrin)
-
Curcumin